AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
200.50
+19.50 (10.77%)
Mar 24, 2026, 1:58 PM CST
Market Cap15.49B +219.7%
Revenue (ttm)n/a
Net Income-447.41M
EPS-5.26
Shares Out85.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume965,638
Average Volume688,668
Open183.00
Previous Close181.00
Day's Range181.00 - 208.50
52-Week Range36.30 - 226.00
Beta0.22
RSI51.79
Earnings DateMar 27, 2026

About AP Biosciences

AP Biosciences Inc researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements